Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Jan 5:10:1.
doi: 10.1186/1471-2466-10-1.

Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study

David Price  1 , Anne Robertson, Kevin Bullen, Cynthia Rand, Rob Horne, Heribert Staudinger
Affiliations
Randomized Controlled Trial

Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study

David Price et al. BMC Pulm Med. .

Abstract

Background: Poor adherence with prescribed asthma medication is a major barrier to positive treatment outcomes. This study was designed to determine the effect of a once-daily administration of mometasone furoate administered via a dry powder inhaler (MF-DPI) on treatment adherence compared with a twice-daily administration.

Methods: This was a 12-week open-label study designed to mimic an actual clinical setting in patients >or=12 years old with mild-to-moderate persistent asthma. Patients were randomized to receive MF-DPI 400 microg once-daily in the evening or MF-DPI 200 microg twice-daily. Adherence was assessed primarily using the number of actual administered doses reported from the device counter divided by the number of scheduled doses. Self-reports were also used to determine adherence. Health-related quality of life, healthcare resource utilization, and days missed from work or school were also reported.

Results: 1233 patients were randomized. The mean adherence rates, as measured by the automatic dose counter, were significantly better (P < 0.001) with MF-DPI 400 microg once-daily in the evening (93.3%) than with MF-DPI 200 microg twice-daily (89.5%). Mean adherence rates based on self-reports were also significantly better (P < 0.001) with MF-DPI 400 microg QD PM (97.2%) than with MF-DPI 200 microg twice-daily (95.3%). Adherence rates were lower in adolescents (12-17 years old). Health-related quality of life improved by 20% in patients using MF-DPI once-daily in the evening and by 14% in patients using MF-DPI twice-daily. Very few (<8%) patients missed work/school.

Conclusion: Mean adherence rates were greater with a once-daily dosing regimen of MF-DPI than with a twice-daily dosing regimen.This trial was completed prior to the ISMJE requirements for trial registration.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Subject Disposition. MF-DPI = mometasone furoate administered via a dry powder inhaler.
Figure 2
Figure 2
Mean adherence to treatment. Adherence was calculated as administered doses divided by scheduled doses × 100, as measured by dose counter and patient self-report. Error bars represent standard error of the mean. *P < 0.001. BID = twice-daily; MF-DPI = mometasone furoate administered via a dry powder inhaler; QD = once-daily.
Figure 3
Figure 3
Physician's evaluation of therapeutic response. Response expressed as mean relative to baseline. P = not significant. MF-DPI = mometasone furoate administered via a dry powder inhaler.
Figure 4
Figure 4
Mean percent change in HRQOL. Changes from baseline in HRQOL were measured by ITG-ASF scores in subjects ≥16 years of age. HRQOL = health-related quality of life; ITG-ASF = Integrated Therapeutics Group-Asthma Short Form; MF-DPI = mometasone furoate administered via a dry powder inhaler; QD = once-daily.
See this image and copyright information in PMC

References

    1. Global Strategy for Asthma Management and Prevention. http://www.ginasthma.com/Guidelineitem.asp??l1=2&l2=1&intId=60
    1. British guideline on the management of asthma: revised edition. http://www.brit-thoracic.org.uk/ClinicalInformation/Asthma/AsthmaGuideli...
    1. Chmelik F, Doughty A. Objective measurements of compliance in asthma treatment. Ann Allergy. 1994;73(6):527–532. - PubMed
    1. Onyirimba F, Apter A, Reisine S, Litt M, McCusker C, Connors M, ZuWallack R. Direct clinician-to-patient feedback discussion of inhaled steroid use: its effect on adherence. Ann Allergy Asthma Immunol. 2003;90(4):411–415. - PubMed
    1. Bender B, Milgrom H, Rand C. Nonadherence in asthmatic patients: is there a solution to the problem? Ann Allergy Asthma Immunol. 1997;79(3):177–185. - PubMed

Publication types

MeSH terms